CAB

Suvoda Expands Board of Directors With Addition of Clinical Trial Veteran Irena Webster

Retrieved on: 
Mardi, juin 20, 2023
Central nervous system, CAB, Clinical data management, American Opportunity Tax Credit, Culture, Public, Biotechnology, Neurodegenerative disease, New York Medical College, Element, IRT, CNS, Science, Biometrics, Patient, Novo Nordisk, IDH1, Knowledge, Shirin David, Cardiology, Therapy, Psychiatry, Neurology, Pharmaceutical industry, Nursing

PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.

Key Points: 
  • PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.
  • Webster is a seasoned global drug development leader with over two decades of experience at sponsor, CRO, and site levels.
  • She has led global clinical trial strategy and execution in a myriad of therapeutic areas including neurology, psychiatry, oncology, cardiology, and rare disease, contributing to multiple NDAs and sNDAs.
  • In addition to joining the board of directors, Webster also serves on the Suvoda customer advisory board (CAB).

Suvoda Expands Board of Directors With Addition of Clinical Trial Veteran Irena Webster

Retrieved on: 
Mardi, juin 20, 2023
Central nervous system, CAB, Clinical data management, American Opportunity Tax Credit, Culture, Public, Biotechnology, Neurodegenerative disease, New York Medical College, Element, IRT, CNS, Science, Biometrics, Patient, Novo Nordisk, IDH1, Knowledge, Shirin David, Cardiology, Therapy, Psychiatry, Neurology, Pharmaceutical industry, Nursing

PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.

Key Points: 
  • PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.
  • Webster is a seasoned global drug development leader with over two decades of experience at sponsor, CRO, and site levels.
  • She has led global clinical trial strategy and execution in a myriad of therapeutic areas including neurology, psychiatry, oncology, cardiology, and rare disease, contributing to multiple NDAs and sNDAs.
  • In addition to joining the board of directors, Webster also serves on the Suvoda customer advisory board (CAB).

Promosome LLC Sues Moderna, Pfizer, and BioNTech for COVID-19 Vaccine Patent Infringement

Retrieved on: 
Mercredi, juin 7, 2023
Vaccine, 1836 U.S. Patent Office fire, BioNTech, Patent, CAB, JES, COVID-19, Messenger, Moderna, SAN, Scripps Research, Pharmaceutical industry, Pfizer

SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.

Key Points: 
  • SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.
  • The suits allege that the mRNA-based COVID-19 vaccines produced by these companies violate patented technology owned by Promosome.
  • While Moderna did not license the '179 Patent, mRNA sequence reverse engineering shows that Moderna took the patented technology for its vaccine, Spikevax®.
  • The second lawsuit, against Pfizer and BioNTech, alleges that Pfizer and BioNTech's joint COVID-19 vaccine Comirnaty® willfully infringes the '179 Patent.

BioAtla to Participate in the Jefferies Healthcare Conference

Retrieved on: 
Mercredi, mai 31, 2023
Conditional, NY, Therapy, CAB, Conference, SAN, Pharmaceutical industry

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.

Key Points: 
  • SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.

Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe

Retrieved on: 
Lundi, mai 22, 2023
Software, Research, General Health, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Clinical Trials, Science, Nanotechnology, Biotechnology, Health, Other Science, Abstract, Society, CAB, SLAS, Government, Full-time equivalent, Chemistry, Literature, Patient, Doe, Drug discovery, Exhibition, Biology, Ecosystem, AI, Laboratory automation, Conference, Automation, Medical device

The SLAS Conference is Europe’s premiere venue for industry, government and academic researchers, developers and providers of laboratory automation technology innovation.

Key Points: 
  • The SLAS Conference is Europe’s premiere venue for industry, government and academic researchers, developers and providers of laboratory automation technology innovation.
  • “At Exscientia, our mission is to encode and automate drug discovery.
  • We believe that within this decade the design of all new drug candidates will be augmented with AI.
  • I am delighted to showcase at SLAS Europe how our recent technology advances enable and drive our projects,” said Dr Garry Pairaudeau, Chief Technology Officer at Exscientia.

Canadian Council for Aboriginal Business welcomes Maple Leaf Sports and Entertainment as a Procurement Champion

Retrieved on: 
Vendredi, mai 19, 2023
CCAB, CAB, Maple Leaf Sports & Entertainment, Bull, Aborigine, MLSE, Certification, Organization, Council, Inclusion, Entertainment, Whaling

TORONTO, May 19, 2023 (GLOBE NEWSWIRE) -- Maple Leaf Sports and Entertainment (MLSE) joins Canadian Council for Aboriginal Business (CCAB) as they focus on Indigenous procurement through CCAB’s Supply Change™ program.

Key Points: 
  • TORONTO, May 19, 2023 (GLOBE NEWSWIRE) -- Maple Leaf Sports and Entertainment (MLSE) joins Canadian Council for Aboriginal Business (CCAB) as they focus on Indigenous procurement through CCAB’s Supply Change™ program.
  • Having MLSE join CCAB signifies a big step forward, as they are the first professional sports franchise in Canada to become a CCAB Aboriginal Procurement Champion.
  • MLSE will participate in CCAB’s Supply Change™ program, joining 126 procurement champions to further Indigenous supplier development through CCAB’s network of over 1,200 Certified Aboriginal Businesses (CAB) nationally.
  • CAB designation assists organizations with identifying Aboriginal businesses to incorporate into their supply chains.

Askel Healthcare has appointed globally renowned orthopedic surgeons and sports medicine specialists to its new Clinical Advisory Board to drive change in the treatment of knee cartilage repair

Retrieved on: 
Mercredi, mai 17, 2023
Sport, Weight-bearing, CAB, Olympic Games, Elective surgery, Cartilage, Mannerheimintie, ICRS, Rehabilitation, Leg, Axel (name), Cell, Knee, Medial knee injuries, MD, Principal, Sports medicine, Environment, EEST, Dentistry, Medical device, Nursing, Terveystalo

HELSINKI, May 17, 2023 /PRNewswire/ -- Askel Healthcare, a Finnish medical technology company offering a new method for the treatment of knee cartilage defects, has established a Clinical Advisory Board (CAB) representing globally renowned orthopedic surgeons and sports medicine specialists in knee cartilage repair.

Key Points: 
  • HELSINKI, May 17, 2023 /PRNewswire/ -- Askel Healthcare, a Finnish medical technology company offering a new method for the treatment of knee cartilage defects, has established a Clinical Advisory Board (CAB) representing globally renowned orthopedic surgeons and sports medicine specialists in knee cartilage repair.
  • In the first phase of commercialization, Askel Healthcare is targeting the U.S. cartilage repair market with the COPLA® implant.
  • Supported by the high-level Clinical Advisory Board, the company aims to become the global standard of surgical knee cartilage repair.
  • The Clinical Advisory Board consists of internationally recognized specialists in the treatment of cartilage damage.

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Jeudi, mai 11, 2023
Therapy, CAB, LMS, Head, G&A, Lung cancer, Conditional, ASCO, CTC, Soft tissue, American Society of Clinical Oncology, AXL, Team Impulse, SAN, Annual general meeting, Webcast, Recurrence, R, PD-1, Research, FDA, Adenocarcinoma, Society, Food, Pharmaceutical industry, Vaccine, Platinum, Cryptocurrency, NSCLC, Patient

Research and development (R&D) expenses were $21.7 million for the quarter ended March 31, 2023 compared to $16.9 million for the same quarter in 2022.

Key Points: 
  • Research and development (R&D) expenses were $21.7 million for the quarter ended March 31, 2023 compared to $16.9 million for the same quarter in 2022.
  • General and administrative (G&A) expenses were $7.2 million for the quarter ended March 31, 2023 compared to $7.4 million for the same quarter in 2022.
  • Net loss for the first quarter ended March 31, 2023 was $27.5 million compared to a net loss of $24.3 million for the same quarter in 2022.
  • The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, May 11, 2023, at 4:30 pm Eastern Time.

BioAtla to Participate in the JMP Securities Life Sciences Conference

Retrieved on: 
Lundi, mai 8, 2023
Conditional, Therapy, CAB, Conference, SAN, Pharmaceutical industry

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the JMP Securities Life Sciences Conference, to be held in New York, NY, from May 15-16, 2023.

Key Points: 
  • SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the JMP Securities Life Sciences Conference, to be held in New York, NY, from May 15-16, 2023.

Project Managers Can Play a Vital Role in Aligning IT Change Management and Project Management for Better Business Outcomes, Says Info-Tech Research Group

Retrieved on: 
Vendredi, mai 5, 2023
Organization, Headache, Tackle, CAB, Research, Intake, Risk management, Industrial design

However, aligning IT change management with project management can pose significant challenges, requiring IT leaders to coordinate and prioritize efforts.

Key Points: 
  • However, aligning IT change management with project management can pose significant challenges, requiring IT leaders to coordinate and prioritize efforts.
  • "Misalignment between IT change management and project management leads to headaches for both practices," says Benedict Chang , senior advisory analyst at Info-Tech Research Group.
  • To enhance the integration of change and project management, it is suggested in the new resource that organizations establish touchpoints between IT change management and project management at key stages in the change and project lifecycles.
  • The research shows that one of the keys to achieving business satisfaction with IT is ensuring IT satisfaction with change management.